Baseline clinical characteristics and surface marker expression in the entire cohort and both the MATRix-treated and non-MATRix–treated subgroups
| . | Entire cohort (n=242) . | MATRix (n=174) . | Non-MATRix (n=68) . | . | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| N (%) . | Missing . | N (%) . | Missing . | N (%) . | Missing . | P value . | ||||
| Male | 144 | (60) | — | 108 | (62) | — | 36 | (53) | — | .24 |
| Age >60 y | 154 | (64) | — | 95 | (55) | — | 59 | (87) | — | <.01 |
| Median age | 65 | Range, 23-84 | 62 | Range, 23-77 | 73 | Range, 34-84 | — | |||
| PS ≤ 1 | 146 | (64) | 14 | 121 | (75) | 13 | 25 | (37) | 1 | <.01 |
| ASCT | 104 | (44) | 3 | 99 | (58) | 2 | 5 | (7) | 1 | <.01 |
| WBRT | 22 | (9) | 2 | 20 | (12) | 2 | 2 | (3) | — | <.01 |
| MYC positive (>40%) | 119 | (60) | 44 | 89 | (62) | 31 | 30 | (55) | 13 | — |
| BCL2 positive (>50%) | 126 | (59) | 28 | 82 | (54) | 21 | 44 | (72) | 7 | — |
| BCL6 positive | 199 | (88) | 15 | 153 | (93) | 10 | 46 | (73) | 5 | <.01 |
| CD10 positive | 61 | (27) | 14 | 42 | (25) | 8 | 19 | (31) | 6 | .65 |
| MUM1 positive | 216 | (94) | 12 | 154 | (94) | 10 | 62 | (97) | 4 | .71 |
| Double expressor | 67 | (40) | 73 | 46 | (40) | 58 | 21 | (40) | 15 | 1.00 |
| Overall response rate | 172 | (74) | 9 | 133 | (79) | 5 | 39 | (61) | 4 | .01 |
| . | Entire cohort (n=242) . | MATRix (n=174) . | Non-MATRix (n=68) . | . | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| N (%) . | Missing . | N (%) . | Missing . | N (%) . | Missing . | P value . | ||||
| Male | 144 | (60) | — | 108 | (62) | — | 36 | (53) | — | .24 |
| Age >60 y | 154 | (64) | — | 95 | (55) | — | 59 | (87) | — | <.01 |
| Median age | 65 | Range, 23-84 | 62 | Range, 23-77 | 73 | Range, 34-84 | — | |||
| PS ≤ 1 | 146 | (64) | 14 | 121 | (75) | 13 | 25 | (37) | 1 | <.01 |
| ASCT | 104 | (44) | 3 | 99 | (58) | 2 | 5 | (7) | 1 | <.01 |
| WBRT | 22 | (9) | 2 | 20 | (12) | 2 | 2 | (3) | — | <.01 |
| MYC positive (>40%) | 119 | (60) | 44 | 89 | (62) | 31 | 30 | (55) | 13 | — |
| BCL2 positive (>50%) | 126 | (59) | 28 | 82 | (54) | 21 | 44 | (72) | 7 | — |
| BCL6 positive | 199 | (88) | 15 | 153 | (93) | 10 | 46 | (73) | 5 | <.01 |
| CD10 positive | 61 | (27) | 14 | 42 | (25) | 8 | 19 | (31) | 6 | .65 |
| MUM1 positive | 216 | (94) | 12 | 154 | (94) | 10 | 62 | (97) | 4 | .71 |
| Double expressor | 67 | (40) | 73 | 46 | (40) | 58 | 21 | (40) | 15 | 1.00 |
| Overall response rate | 172 | (74) | 9 | 133 | (79) | 5 | 39 | (61) | 4 | .01 |
P values refer to χ2 testing MATRix- vs non-MATRix–treated subgroup. Significant P values are indicated in bold.
WBRT, whole-brain radiotherapy.